Cell line · CVCL_1906
Papers50
1 to 20 of 50
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Distinct mechanisms of neutralization by antibodies targeting a conserved pneumovirus F epitope. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Punicalin targets RSV glycoprotein and fusion protein at non-overlapping sites to prevent viral escape. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Long-term stability of the GMP-compliant recombinant BCG vaccine against human RSV under quality control analyses. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Regulation of antiviral immunity by PD-1 during respiratory syncitial virus infection and upon vaccination. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Respiratory Syncytial Virus Nonstructural Protein 1 Inhibits Production of Cytokines and Chemokines by Differentiated Primary Nasal Epithelial Cells Cultured at Air-Liquid Interface. | J Innate Immun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Viral infection and brain inflammation with seizures in PARK7 deficiency. | J Hum Immun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Preclinical characterisation of the protective capacity of an anti-nucleoprotein hRSV monoclonal antibody. | EBioMedicine | 2026 | Its Methods give the RRID and name the line | PubMed | |
Molecular mechanism of resistance to lonafarnib conferred by mutations in the cysteine-rich region of respiratory syncytial virus fusion glycoprotein and discovery of a lonafarnib-derived antiviral PROTAC. | J Virol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Respiratory syncytial virus downregulates the airway aryl hydrocarbon receptor pathway: implication for the development of a novel therapeutic target. | Am J Physiol Lung Cell Mol Physiol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| No evidence of direct activation of human neutrophil responses by multivalent prefusion trimeric SARS-CoV-2 Spike protein ex vivo. | PLoS One | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Linking LEDGF/p75 Overexpression With Microsatellite Instability and KRAS Mutations: A Small-Scale Study in Colorectal Cancer. | Cancer Control | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Advancing respiratory virus diagnostics: integrating the nasal IFN-I score for improved viral detection. | EBioMedicine | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Targeting RSV-neutralizing B cell receptors with anti-idiotypic antibodies. | Cell Rep | 2024 | Its Methods give the RRID and name the line | PubMed | |
| A signature of four ferroptosis-related genes in laryngeal squamous cell carcinoma. | Transl Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Fully automated viability and toxicity screening—A reliable all‐in‐one attempt | Cancer Med | 2024 | Its Methods give the RRID and name the line | PubMed Central | |
| TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry. | Cell | 2023 | Its Methods give the RRID and name the line | PubMed | |
| A bat MERS-like coronavirus circulates in pangolins and utilizes human DPP4 and host proteases for cell entry. | Cell | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Role of CCR3 in respiratory syncytial virus infection of airway epithelial cells. | iScience | 2021 | Its Methods give the RRID and name the line | PubMed | |
| The Extensive and Expensive Impacts of HEp-2 [HeLa], Intestine 407 [HeLa], and Other False Cell Lines in Journal Publications. | SLAS Discov | 2021 | Cellosaurus cites it | PubMed | |
| Adaptation of the HEp-2 cell line to totally animal-free culture systems and real-time analysis of cell growth. | Biotechniques | 2021 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1906/papers